文献速递认知障碍与痴呆

真实世界视觉判读与淀粉样蛋白PET定量判读的一致性

Concordance Between Amyloid-PET Quantification and Real-World Visual Reads.
PubMed 文献 · JAMA Neurol · 2025-01-01

该横断面质量改进研究基于IDEAS研究数据,比较了294家影像中心局部视觉判读与中心定量Centiloid分类的一致性,发现86.3%的扫描判读一致(κ=0.72),支持真实临床实践中淀粉样蛋白PET视觉判读的有效性。

要点

  • 视觉判读与定量分类总体一致率为86.3%,Cohen κ=0.72。
  • 10-40 CL临界阳性区的扫描更容易出现判读不一致。
  • 女性、白人种族及使用[18F]flutemetamol或[18F]florbetaben与更高一致性相关。

核心结论

  • 真实临床实践中局部视觉判读与中心定量分类之间具有高度一致性,支持淀粉样蛋白PET视觉判读的有效性。

研究设计与样本

  • 横断面质量改进研究,使用影像痴呆-淀粉样蛋白扫描证据(IDEAS)研究数据,收集于2016年2月至2018年1月,分析于2021年12月至2023年4月。
  • 设置包括美国294家影像中心,由痴呆专家从其临床实践中招募65岁及以上、因认知下降考虑阿尔茨海默病的Medicare受益人。

主要发现

  • 6332次扫描(61%)被视觉判读为阳性,6121次(59%)被定量分类为阳性。
  • 视觉判读与定量分类的一致率为86.3%(95%CI,85.7%-87.0%;Cohen κ=0.72;95%CI,0.70-0.73)。
  • 5519次(53%)扫描为视觉和定量均阳性(V+/Q+),3416次(33%)为两者均阴性(V-/Q-),813次(8%)为V+/Q-,602次(6%)为V-/Q+。
  • 女性(女性:4581/5241 [87.4%];男性:4354/5109 [85.2%];P=.001)、白人种族(白人:7900/9125 [86.6%];非白人:1035/1225 [84.5%];P=.046)以及使用[18F]flutemetamol(559/628 [89.0%])和[18F]florbetaben(2664/3032 [87.9%])相较于[18F]florbetapir(5712/6690 [85.4%])(P<.001)与更高的视觉-定量一致性相关。
  • 位于10-40 CL临界阳性区内的扫描更可能出现判读不一致。

关键数值与推荐

  • 采用基于尸检的先验阈值24.4 CL定量定义扫描阳性。
  • 视觉判读由当地放射科医生或核医学医生按照批准指南进行,判读为阳性或阴性。

临床怎么用

  • 在真实临床实践中,淀粉样蛋白PET的视觉判读结果与中心定量分类高度一致,可支持临床决策。
  • 对于位于10-40 CL临界区的扫描,临床医生应警惕视觉判读与定量结果不一致的可能性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: With increased payer coverage and the advent of antiamyloid therapies, clinical use of amyloid positron emission tomography (PET) is likely to increase to help guide the diagnosis and treatment of patients with cognitive impairment. However, unlike most previous research studies, in clinical practice, scan acquisition is less standardized, interpretation typically relies purely on visual reads rather than scan quantification, and patients have more frequent comorbidities, all of which might compromise test accuracy. OBJECTIVE: To compare visual interpretation of amyloid-PET in real-world clinical settings to scan interpretation based on central quantification, in order to assess the accuracy of clinical reads. DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional quality improvement study used data from the Imaging Dementia-Evidence for Amyloid Scanning study, collected between February 2016 and January 2018 and analyzed between December 2021 and April 2023. The setting included 294 imaging facilities in the US. Medicare beneficiaries 65 years or older with cognitive decline for whom Alzheimer disease was a diagnostic consideration were recruited by dementia specialists from their clinical practices. EXPOSURES: Amyloid-PET with [18F]florbetapir, [18F]florbetaben, or [18F]flutemetamol. MAIN OUTCOMES AND MEASURES: PET scans were visually interpreted as positive or negative by local radiologists or nuclear medicine physicians following approved guidelines. Independently, scans were centrally processed and quantified using the standardized Centiloid (CL) scale. We applied an a priori autopsy-based threshold of 24.4 CL to quantitatively define scan positivity. RESULTS: Of 18 293 participants included in the parent study, scan images were available for 10 774 (59%), of which Centiloids were successfully calculated for 10 361 (96%). Median (IQR) patient age was 75 (71-80) years; 5245 patients (51%) were female, 6500 (63%) had mild cognitive impairment, and 3861 (37%) had dementia). Participants self-reported the following races and ethnicities: 1 Alaska Native (0%), 23 American Indian (0.2%), 188 Asian (1.8%), 316 Black (3.1%), 449 Hispanic or Latino (4.3%), 8 Native Hawaiian or Other Pacific Islander (0.1%), and 9125 White (88.2%). A total of 6332 scans (61%) were visually read as positive, and 6121 (59%) were quantitatively positive. Agreement between visual reads and quantitative classification was 86.3% (95% CI, 85.7%-87.0%; Cohen κ = 0.72; 95% CI, 0.70-0.73). A total of 5519 (53%) scans were positive visually and quantitatively (V+/Q+), 3416 (33%) were negative by both (V-/Q-), 813 (8%) were V+/Q-, and 602 (6%) were V-/Q+. Female sex (female: 4581/5241 [87.4%]; male: 4354/5109 [85.2%]; P =.001), White race (White race: 7900/9125 [86.6%]; non-White race: 1035/1225 [84.5%]; P =.046), and use of [18F]flutemetamol and [18F]florbetaben ([18F]flutemetamol: 559/628 [89.0%]; [18F]florbetaben: 2664/3032 [87.9%]; [18F]florbetapir: 5712/6690 [85.4%]; P <.001), compared with [18F]florbetapir, were associated with higher visual-quantitative concordance. Scans within a 10- to 40-CL borderline positivity zone were more likely to be discordant. CONCLUSIONS AND RELEVANCE: This cross-sectional study found high concordance between local visual reads and central quantification of clinical amyloid-PET scans, supporting the validity of amyloid-PET visual reads in real-world clinical practice.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Zeltzer E, Schonhaut DR, Mundada NS, et al. Concordance Between Amyloid-PET Quantification and Real-World Visual Reads. JAMA Neurol. 2025. PMID: 40720133. doi:10.1001/jamaneurol.2025.2218

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。